Amantadine
- Generic Name
- Amantadine
- Brand Names
- Gocovri, Osmolex
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N
- CAS Number
- 768-94-5
- Unique Ingredient Identifier
- BF4C9Z1J53
- Background
An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
- Indication
For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
- Associated Conditions
- Dyskinesia, Extrapyramidal disorder caused by neuroleptic drugs without Tardive dyskinesia, Influenza A Virus Infection, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Parkinsonism
The Effect of Amantadine As Add-on Therapy for Motor Fluctuations in Advanced Parkinson's Disease: a Randomized Double-blinded Placebo-controlled Trial
- Conditions
- Parkinson Disease (PD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-10
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 132
- Registration Number
- NCT06817200
- Locations
- 🇫🇷
CHU Toulouse, Toulouse, France
Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness
- Conditions
- ElectroencephalographyConsciousness DisordersAmantadine
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Azienda Sanitaria dell'Alto Adige
- Target Recruit Count
- 18
- Registration Number
- NCT06443827
- Locations
- 🇮🇹
Hospital of Vipiteno, Vipiteno, Bolzano, Italy
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
- Conditions
- Traumatic Brain Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- SHINKEI Therapeutics, Inc
- Target Recruit Count
- 45
- Registration Number
- NCT06253923
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
- Conditions
- Long COVIDPost-Acute COVID-19 Syndrome
- Interventions
- Other: Provider CounselingOther: Physical, Occupational, Speech TherapyOther: Medications for symptoms management
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT06234462
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Amantadine Therapy for Cognitive Impairment in Long COVID
- Conditions
- Long COVIDPost-COVID19 ConditionPost-Acute COVID19 Syndrome
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 60
- Registration Number
- NCT06055244
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States
Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU
- Conditions
- Traumatic Brain Injury
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 150
- Registration Number
- NCT06052787
- Locations
- 🇪🇬
Faculty of medicine - Ain shams university, Cairo, Egypt
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
- Conditions
- Multiple SclerosisFatigue
- Interventions
- Device: Transcranial Magnetic Stimulation
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Hospital San Carlos, Madrid
- Target Recruit Count
- 144
- Registration Number
- NCT05809414
- Locations
- 🇪🇸
Hospital General Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Clínico San Carlos, Madrid, Spain
🇪🇸Hospital Puerta del Mar, Cadiz, Spain
The Effect of Amantadine on Post-COVD-19 Fatigue
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05667077
- Locations
- 🇮🇷
Shohada Tajrish Hospital, Tehran, Iran, Islamic Republic of
Antihistamines, Amantadine and Evolution of the SARS-CoV-2 Infection
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Consorci Sanitari de Terrassa
- Target Recruit Count
- 140660
- Registration Number
- NCT05504057
- Locations
- 🇪🇸
Hospital de Terrassa, Terrassa, Barcelona, Spain
🇪🇸Hospital of Terrassa, Terrassa, Barcelona, Spain
Amantadine for Neuroenhancement in Acute Patients Study
- First Posted Date
- 2022-07-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 50
- Registration Number
- NCT05479032
- Locations
- 🇩🇪
Universitätsklinikum Tübingen, Tübingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.